Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau
- Authors
- Jeong, Hyeanjeong; Shin, Seulgi; Lee, Jun-Seok; Lee, Soo Hyun; Baik, Ja-Hyun; Lim, Sungsu; Kim, Yun Kyung
- Issue Date
- 1-9월-2019
- Publisher
- MDPI
- Keywords
- histone deacetylase inhibitor; tau acetylation; tau aggregation; Alzheimer' s disease
- Citation
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.20, no.17
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Volume
- 20
- Number
- 17
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/62952
- DOI
- 10.3390/ijms20174283
- ISSN
- 1661-6596
- Abstract
- Epigenetic remodeling via histone acetylation has become a popular therapeutic strategy to treat Alzheimer's disease (AD). In particular, histone deacetylase (HDAC) inhibitors including M344 and SAHA have been elucidated to be new drug candidates for AD, improving cognitive abilities impaired in AD mouse models. Although emerged as a promising target for AD, most of the HDAC inhibitors are poorly selective and could cause unwanted side effects. Here we show that tau is one of the cytosolic substrates of HDAC and the treatment of HDAC inhibitors such as Scriptaid, M344, BML281, and SAHA could increase the level of acetylated tau, resulting in the activation of tau pathology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.